This BRAF mutant, besides promoting cancer initiation through the enhancement of thyroid carcinoma cell growth rate and survival, drives cancer progression through the inhibition of sodium-iodide symporter expression that, in turn, determines iodine unresponsiveness [9]. The gene discussed is SLC5A5; the disease is cancer.